

Editorial

# Colorectal Cancer Research: Basic, Preclinical, and Clinical Approaches

Jean-François Beaulieu <sup>1,2</sup> 

<sup>1</sup> Laboratory of Intestinal Physiopathology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; Jean-Francois.Beaulieu@USherbrooke.ca; Tel.: +1-819-821-8000 (ext. 75269)

<sup>2</sup> Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

Received: 4 February 2020; Accepted: 6 February 2020; Published: 11 February 2020



Colorectal cancer remains one of the deadliest cancers worldwide. It has become evident that further efforts in colorectal cancer research are required, from providing a better understanding of the cellular and molecular mechanisms leading to colorectal neoplasm initiation and progression from adenoma to metastasis, to generating reliable non-invasive detection tests for identifying lesions at early stages, as well as refining the current therapeutic and personalized approaches and developing new ones. The aim of this Special Issue is to cover all aspects of colorectal cancer research, including basic, preclinical, and clinical approaches.

The original articles of this Special Issue present innovative findings toward the design of new strategies that may contribute to the fight against colorectal cancer cells, such as treatments that enhance apoptosis-related mechanisms [1,2], chemosensitivity [3–6] and/or radiotherapy [7], and the characterization of new pathways that lead to the identification of specific biomarkers and/or decipher unique mechanisms underlying colorectal cancer initiation and progression. These mechanisms include the transcriptional regulation of DNA repair proteins [8]; the epigenetic regulation of the zinc finger E-box-binding homeobox 1 [9] and the expression of the (pro)renin receptor [10], WNT-11 [11], and calcium and calcium-activated potassium channels [12]; the contribution of immune cells in the tumor microenvironment [13]; and the identification of genetic aberrations that occur during the transition from adenoma to carcinoma [14]. The development of tools for preclinical research is also a key research area, such as the establishment of tumor models at the individual patient level [15] and the refinement of clinical approaches for improving the survival of patients with metastatic colorectal cancer [16–19].

Review articles have summarized the latest developments of clinical issues related to the management of improving chemotherapeutic approaches for metastatic colorectal cancer [20–22], the characterization of the hallmarks of serrated colorectal lesions [23] and immune-mediated intestinal disorders that can be associated with small bowel carcinoma [24], as well as the current state of knowledge of specific facets of colorectal cancer research such as oncogenic tyrosine kinase signaling [25], integrin  $\alpha6\beta4$  [26], and epigenetic mechanisms by which long non-coding RNAs regulate gene expression [27].

The variety of the content of this Special Issue devoted to colorectal cancer illustrates the need for investigating the cellular basis of this disease from every angle in order to develop efficient screening and treatment strategies that can significantly impact the quality of life of the patients. I would like to thank all of the authors that have contributed to the articles of this Special Issue for their work.

**Conflicts of Interest:** The author declares no conflict of interest.

## References

1. Caceres, B.; Ramirez, A.; Carrillo, E.; Jimenez, G.; Grinan-Lison, C.; Lopez-Ruiz, E.; Jimenez-Martinez, Y.; Marchal, J.A.; Boulaiz, H. Deciphering the Mechanism of Action Involved in Enhanced Suicide Gene Colon Cancer Cell Killer Effect Mediated by Gef and Apoptin. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
2. Mahalingam, D.; Carew, J.S.; Espitia, C.M.; Cool, R.H.; Giles, F.J.; de Jong, S.; Nawrocki, S.T. Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
3. Baldari, S.; Di Rocco, G.; Heffern, M.C.; Su, T.A.; Chang, C.J.; Toietta, G. Effects of Copper Chelation on BRAF(V600E) Positive Colon Carcinoma Cells. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
4. Han, Y.; Chen, P.; Zhang, Y.; Lu, W.; Ding, W.; Luo, Y.; Wen, S.; Xu, R.; Liu, P.; Huang, P. Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. *Cancers* **2019**, *11*. [[CrossRef](#)]
5. Li, J.M.; Huang, Y.C.; Kuo, Y.H.; Cheng, C.C.; Kuan, F.C.; Chang, S.F.; Lee, Y.R.; Chin, C.C.; Shi, C.S. Flavopereirine Suppresses the Growth of Colorectal Cancer Cells through P53 Signaling Dependence. *Cancers* **2019**, *11*. [[CrossRef](#)]
6. Maier, E.; Attenberger, F.; Tiwari, A.; Lettau, K.; Rebholz, S.; Fehrenbacher, B.; Schaller, M.; Gani, C.; Toulany, M. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. *Cancers* **2019**, *11*. [[CrossRef](#)]
7. Chen, Y.H.; Wang, C.W.; Wei, M.F.; Tzeng, Y.S.; Lan, K.H.; Cheng, A.L.; Kuo, S.H. Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)]
8. Babeu, J.P.; Wilson, S.D.; Lambert, E.; Levesque, D.; Boisvert, F.M.; Boudreau, F. Quantitative Proteomics Identifies DNA Repair as a Novel Biological Function for Hepatocyte Nuclear Factor 4alpha in Colorectal Cancer Cells. *Cancers* **2019**, *11*. [[CrossRef](#)]
9. Kim, K.S.; Jeong, D.; Sari, I.N.; Wijaya, Y.T.; Jun, N.; Lee, S.; Yang, Y.G.; Lee, S.H.; Kwon, H.Y. miR551b Regulates Colorectal Cancer Progression by Targeting the ZEB1 Signaling Axis. *Cancers* **2019**, *11*. [[CrossRef](#)]
10. Beitia, M.; Solano-Iturri, J.D.; Errarte, P.; Calvete-Candenas, J.; Loizate, A.; Etxezarraga, M.C.; Sanz, B.; Larrinaga, G. (Pro)renin Receptor Expression Increases throughout the Colorectal Adenoma-Adenocarcinoma Sequence and It Is Associated with Worse Colorectal Cancer Prognosis. *Cancers* **2019**, *11*. [[CrossRef](#)]
11. Gorrone-Etxebarria, I.; Aguirre, U.; Sanchez, S.; Gonzalez, N.; Escobar, A.; Zabalza, I.; Quintana, J.M.; Vivanco, M.D.; Waxman, J.; Kypta, R.M. Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
12. Ibrahim, S.; Dakik, H.; Vandier, C.; Chautard, R.; Paintaud, G.; Mazurier, F.; Lecomte, T.; Gueguinou, M.; Raoul, W. Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
13. Mullins, C.S.; Gock, M.; Krohn, M.; Linnebacher, M. Human Colorectal Carcinoma Infiltrating B Lymphocytes Are Active Secretors of the Immunoglobulin Isotypes A, G, and M. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
14. Intarajak, T.; Udomchaiprasertkul, W.; Bunyoo, C.; Yimnoon, J.; Soonklang, K.; Wiriyaikaradecha, K.; Lamlerthton, W.; Sricharunrat, T.; Chaiwiriya Wong, W.; Siriphongpreeda, B.; et al. Genetic Aberration Analysis in Thai Colorectal Adenoma and Early-Stage Adenocarcinoma Patients by Whole-Exome Sequencing. *Cancers* **2019**, *11*. [[CrossRef](#)]
15. Mullins, C.S.; Micheel, B.; Matschos, S.; Leuchter, M.; Burtin, F.; Krohn, M.; Huhns, M.; Klar, E.; Prall, F.; Linnebacher, M. Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research. *Cancers* **2019**, *11*. [[CrossRef](#)]
16. Fenocchio, E.; Colombi, F.; Calella, M.G.; Filippi, R.; Depetris, I.; Chila, G.; Lombardi, P.; Marino, D.; Cagnazzo, C.; Ferraris, R.; et al. Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. *Cancers* **2019**, *11*. [[CrossRef](#)]
17. Primavesi, F.; Stattner, S.; Jager, T.; Gobel, G.; Presl, J.; Tomanova, K.; Buchner, S.; Maglione, M.; Resch, T.; Hutter, J.; et al. Progressive Oncological Surgery Is Associated with Increased Curative Resection Rates and Improved Survival in Metastatic Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)]

18. Rosati, G.; Cordio, S.; Reggiardo, G.; Aprile, G.; Butera, A.; Avallone, A.; Tucci, A.; Novello, G.; Blanco, G.; Caputo, G.; et al. Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials. *Cancers* **2019**, *11*. [[CrossRef](#)]
19. Winter, H.; Rassam, J.; Virdee, P.S.; Goldin, R.; Pitcheshwar, P.; Weaver, K.; Primrose, J.; Berry, D.P.; Wasan, H.S.; Sharma, R.A. Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres. *Cancers* **2019**, *11*. [[CrossRef](#)]
20. Galvano, A.; Incorvaia, L.; Badalamenti, G.; Rizzo, S.; Guarini, A.; Cusenza, S.; Castellana, L.; Barraco, N.; Calo, V.; Cutaia, S.; et al. How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. *Cancers* **2019**, *11*. [[CrossRef](#)]
21. Marmol, I.; Quero, J.; Rodriguez-Yoldi, M.J.; Cerrada, E. Gold as a Possible Alternative to Platinum-Based Chemotherapy for Colon Cancer Treatment. *Cancers* **2019**, *11*. [[CrossRef](#)]
22. Ranieri, G.; Laforgia, M.; Nardulli, P.; Ferraiuolo, S.; Molinari, P.; Marech, I.; Gadaleta, C.D. Oxaliplatin-Based Intra-arterial Chemotherapy in Colo-Rectal Cancer Liver Metastases: A Review from Pharmacology to Clinical Application. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
23. De Palma, F.D.E.; D'Argenio, V.; Pol, J.; Kroemer, G.; Maiuri, M.C.; Salvatore, F. The Molecular Hallmarks of the Serrated Pathway in Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
24. Giuffrida, P.; Vanoli, A.; Arpa, G.; Bonometti, A.; Luinetti, O.; Solcia, E.; Corazza, G.R.; Paulli, M.; Di Sabatino, A. Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge. *Cancers* **2018**, *11*. [[CrossRef](#)] [[PubMed](#)]
25. Mevizou, R.; Sirvent, A.; Roche, S. Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer. *Cancers* **2019**, *11*. [[CrossRef](#)] [[PubMed](#)]
26. Beaulieu, J.F. Integrin  $\alpha 6 \beta 4$  in Colorectal Cancer: Expression, Regulation, Functional Alterations and Use as a Biomarker. *Cancers* **2019**, *12*. [[CrossRef](#)] [[PubMed](#)]
27. Neve, A.; Migliavacca, J.; Capdeville, C.; Schonholzer, M.T.; Gries, A.; Ma, M.; Santhana Kumar, K.; Grotzer, M.; Baumgartner, M. Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma. *Cancers* **2019**, *11*. [[CrossRef](#)]



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).